• Printer Friendly Version
  • Decrease Text Size
  • Increase Text Size
  • PDF

Pediatric Hematology / Oncology

Pediatric Hematology
The Childhood and Adolescent Cancer and Blood Diseases Center at Maria Fareri Children’s Hospital, a member of the Westchester Medical Center Health Network (WMCHealth), is an internationally-recognized, multidisciplinary diagnostic treatment and research center extending comprehensive, quality care while leading breakthrough research in cancer and blood diseases.

Our Mission

The Pediatric Hematology, Oncology, and Stem Cell Transplantation care and research teams at Maria Fareri Children's Hospital provide innovative therapies for childhood cancer and blood disorders, and develop new treatments for preventing these diseases. 

Our dedicated mission includes:

• Providing state-of-the-art and personalized, quality care for pediatric patients
• Developing new preventive, diagnostic, innovative, and therapeutic strategies
• Conducting scholarly clinical, translational, and basic science research
• Implementing translational therapy that incorporates cellular, gene, and regenerative therapeutics, targeted therapy, and personalized curative strategies
• Promoting psychosocial well-being and long-term survivorship
• Educating and mentoring future generations of bright and caring health care professionals in the diagnosis and treatment of children and adolescents with cancer,
  blood and genetic illnesses.

Personalized Care You Can Trust

Twenty-first century treatment for our youngest cancer and blood disease patients means a personalized, targeted approach that’s both focused and gentle—one that reduces toxicity and uses groundbreaking methods to treat cancerous tissues and blood diseases. Under the direction of Mitchell Cairo, MD, Division Chief, Pediatric Hematology, Oncology and Stem Cell Transplantation at Maria Fareri Children's Hospital, our team draws upon expertise in pediatric hematology, oncology, stem cell transplantation, surgery, pathology, genetics, radiation oncology and immunology to personalize this approach for each child.

We specialize in diagnosing, treating, and researching solid tumors, brain tumors, childhood leukemias, bone marrow failure, sickle cell disease, and other hematological illnesses. Click here for a full list of our clinical and therapeutic programs.

Cutting-Edge Research

Each day, we gain expertise, build resources and achieve breakthroughs in the treatment of cancer and blood disease. From bone marrow transplantation to stem cell and gene therapy, we are unlocking treatments and blazing trails to pinpoint the cause, course of personalized treatment, and cure. 

Our investigations are basic, translational, and clinical—meaning that breakthroughs in the laboratory translate directly into patient care. By taking the lead in several trials investigating targeted antibodies, cellular therapy and stem cell transplants, the Center has immediate access to pioneering research that informs therapeutic strategies and enhances quality of care.

Putting Our Patients First

We know, as you do, that each child is unique, and each one deserves the science-based medicine and the holistic support to sustain him or her—in body, mind, and spirit—through the challenges of sickness. From the bedside to behind the scenes, our approaches center on our patients, and from the minute you arrive at the hospital, we’re in this together. 

Active family involvement creates the environment that allows us to provide advanced care, especially through the physical and emotional rigors of prolonged illness. Children in treatment for cancer or blood disorders at Maria Fareri Children’s Hospital may stay here for a while, but they will never feel “hospitalized.” Instead, they will engage will their families, peers, care providers, and others on their journey toward healing.

Please Click Titles for Details


Blood and Marrow Transplant

 

Our Blood and Marrow Transplantation (BMT) Program performs both autologous and allogeneic stem cell transplants.  We have a highly skilled, multidisciplinary team dedicated to the therapeutic use of bone marrow, peripheral blood, cord blood and cellular therapy in the treatment of malignant, non-malignant, and serious blood-related disorders. 

 

Types of Bone Marrow Transplants

 

Autologous bone marrow transplant

For some diseases, the patient’s own stem cells are removed and given back after receiving chemotherapy and/or radiation.  Your doctor will decide on the best donor choice for you after looking at several variables in order to find the most suitable match for the patient.

 

Allogeneic bone marrow transplant

For some diseases, patients cannot use their own stem cells for a transplant so they must use a donor, either related or unrelated.

 

Related donor transplant

Typically patients begin the allogeneic transplant process by trying to identify a relative to be their donor. Siblings are most likely to be a close match for a transplant (based on HLA typing); identical twins are an exact match.

 

Matched unrelated donor transplant

If you don’t have a relative available who is a match, doctors can search international donor registries for an unrelated donor who is a match for you. Read more about finding or becoming a donor.

 

Haploidentical transplants

Half-matched transplants sometimes used to open up the donor pool and make it easier to find a donor.

 

Cord Blood Transplants

Some people choose to donate their cord blood at the time of their baby’s birth.  This cord blood is frozen and can be used for bone marrow transplants.

 

Diseases We Treat

 

Malignant Diseases: 

  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Chronic Myeloid Leukemia
  • Juvenile Myelomonocytic Leukemia
  • Multiple Myeloma
  • Non-Hodgkin Lymphoma (Burkitt, Large Cell, Lymphoblastic, Anaplastic)
  • Hodgkin Lymphoma
  • Neuroblastoma
  • Brain Tumors
  • Wilms Tumor
  • Sarcomas
  • Others

 

Non-Malignant Diseases:

  • Bone Marrow Failure syndromes
  • Hemoglobinopathies
  • Immunodeficiencies (SCID, Wiskott-Aldrich, Hemophagocytic Lymphohistiocytosis (HLH)
  • Metabolic
  • Autoimmune Diseases
  • Myelofibrosis
  • Others

 

Unique Features:

  • FACT Accredited
  • COG Accredited
  • NMDP Accredited
  • Pediatric Blood and Marrow Transplantation Consortium (PBMTC) member
  • Cellular and Tissue Engineering Laboratory “GMP Quality”
  • Cord Blood Diseases & Regenerative Therapy Program
  • Cord Blood Transplantation Program
  • Unrelated Adult Donor Stem Cell Program
  • Haploidentical Stem Cell Program
  • Extracorporeal Photopheresis
  • On-site leukopheresis for peripheral stem cell collection and bone marrow stem cell harvesting
  • T-cell Depletion and Stem Cell Selection Program
  • High-Risk Leukemia Consortium (Lead Institution)
  • Lymphoma Cell Therapy Consortium (Lead Institution)
  • Sickle Cell Transplantation Consortium (Lead Institution)
  • Sarcoma Cell Therapy Consortium (Lead Institution)
  • Ten HEPA Filtered and Positive Pressure Inpatient Rooms
  • Personalized and customized blood, marrow and cellular therapies
  • Multidisciplinary Programs
  • Long-Term Survivors Program

 

Research and Education Highlights:

  • ACGME Accredited Pediatric Hematology, Oncology, and Stem Cell Transplantation Fellowship Program
  • Student, Resident and other Allied Health Professions elective/selectives
  • Tumor Immunology
  • Transplantation Immunology
  • Adoptive Targeted Cellular Therapy
  • Stem Cell Biology, Regenerative, and Hematopoiesis

Return to the top


Hematologic Malignancy (Leukemia/Lymphoma)

The Hematological Malignancy Program consists of a multidisciplinary team focused on the prevention, diagnosis, and treatment of cancers arising in the bone marrow, lymph nodes and other associated organs. The program is also focused on the education of students, residents and fellows who will be conducting scholarly and peer-reviewed clinical, translational and basic research in hematological malignancies.

The Hematological Malignancy Program has several “state of the art” basic, translational and clinical research programs in Acute Leukemias, Non-Hodgkin Lymphoma, Hodgkin Lymphoma and other associated hematological malignancies. Overall the program is equipped to design and deliver customized and personalized therapy for each child and adolescent in the cancer center diagnosed with a hematological malignancy.

Diseases We Treat

Unique Features:

  • Cutting edge customized patient treatment protocols
  • Ten protective isolation hospital rooms for induction therapy and stem cell transplantation
  • Outpatient Infusion Center for patient specific therapies
  • State of the Art Diagnostic Laboratories
  • Local and total body radiation facilities
  • Targeted and developmental Therapeutics
  • Monoclonal antibody and radio-conjugate antibody therapies
  • Comprehensive Stem and Cellular Therapy and Transplantation Program
  • Cellular and Tissue Engineering Laboratory
  • Multidisciplinary team


Research and Education Highlights:

  • ACGME Accredited Pediatric Hematology, Oncology and Stem Cell Transplantation Fellowship Training Program
  • Student, resident and other allied health professional elective/selectives
  • Children’s Oncology Group (COG) Member Institution
  • Childhood, Adolescent and Young Adult Lymphoma Cell Therapy Consortium (LCTC), Lead Institution
  • Childhood, Adolescent and Young Adult Non Hodgkins Lymphoma Translational Research and Treatment
  • Consortium, Lead Institute
  •  Stem Cell Transplantation for Poor Risk Acute Leukemia Consortium, Lead Institution
  • Pediatric Blood and Marrow Transplant Consortium (PBMTC), Member Institution
  • National Marrow Donor Program (NMDP), Member Institution
  • Leukemia and Lymphoma Cancer Genetics Research Program
  • Leukemia and Lymphoma Tumor Immunology and Cellular Therapeutics Research Program


Return to the top


Histiocytic Disorders

The Histiocytosis program consists of a multidisciplinary team focused on the diagnosis and treatment of histiocytic disorders in children and adolescents. Our physicians participate in national and international committees on diagnosis and management of these rare disorders. This program also focuses on the education of students, residents, and fellows who will participate in clinical and laboratory research of the new and innovative protocols for the treatment of histiocytosis.

Histiocytic disorders occur when there is an overproduction of histiocytes or mononuclear phagocytic cells of bone marrow origin. Overproduction of these cells can lead to organ damage and cause disease, based on the type of the cells involved.  Correct and complete pathologic diagnosis is essential because different diseases require different treatment approaches. We focus on the following:

  • Dendritic cell disorders, including Langerhans Cell Histiocytosis (LCH), Juvenile Xanthogranuloma (JXG) and Erdheim Chester Disease (ECD)
  • Macrophage cell disorders, including Hemophagocytic Lymphohistiocytosis (HLH) and Rosai-Dorfman Disease (RD)
  • Malignant histiocytosis, including certain kinds of leukemia and malignant tumors

 

Unique Features:

  • Innovative therapy treatment protocols
  • Outpatient Infusion Center for patients treated for histiocytosis
  • Multidisciplinary services of the pediatric surgery, pathology and radiation medicine for children and adolescents with histiocytic disorders
  • Team of stem cell transplantation specialists

 

Research and Education Highlights:

  • Member Institution of Histiocytosis Society
  • Student, resident and other allied health professional elective education
  • Clinical research on new innovative therapies
  • Education of the parents of children and adolescents afflicted with histiocytic disorders

Return to the top


Neuro-Oncology

Central nervous system (CNS) tumors, which include cancers of the brain and spinal cord, are the second most common malignancies in pediatrics. The successful management and care of children who suffer from them require a coordinated team approach.   Our primary treatment team consists of pediatric neurosurgery, pediatric neuro-oncology, pediatric radiation oncology and advanced practice nursing. These team members are assisted by pediatric neuropathology, neuro-radiology, neurology, endocrinology and nursing specialists. Dedicated psychology, neuropsychology, child life, physical therapy, occupational therapy, nutrition and social services personnel also provide necessary support to patients. Most of these services are available at our Comprehensive Brain Tumor Clinic. All staff are highly trained in providing personal care to children with CNS cancers and are acutely sensitive to the needs and concerns of their families.   In addition to the standard treatment plans and the research protocols of the Children’s Oncology Group, we provide individualized therapy, including the capacity to provide novel cellular and immune modalities. Consultations and second opinions are welcomed.

Diseases We Treat

  • Benign tumors
  • Low to high-grade gliomas
  • Diffuse pontine glioma
  • Optic glioma
  • NF1 and NF2-associated tumors
  • Germ cell tumor
  • Eependymoma
  • Medulloblastoma
  • Typical teratoid/rhabdoid tumor
  • Pituitary tumors
  • Choroid plexus tumors
  • Retinoblastoma
  • PNET
  • Oligodendroglioma
  • Meningioma
  • Tectal tumors
  • Thalamic tumors
  • Anglioglioma
 

Unique Features:

  • Comprehensive “Medical Home” Outpatient Program
  • Individualized therapy for diffuse intrinsic pontine glioma and glioblastoma multiforme
  • Blythedale Children’s Hospital nearby for physical rehabilitation
  • Pediatric Neuro-Surgical Team
  • Cutting edge customized patient treatment protocols
  • Children’s Oncology Group and multicenter clinical trials
  • Neuropsychological testing and follow-up
  • Coordinated team of neuro-oncologists, neurologists, neuroradiologists, radiation therapists and pediatric neurosurgeons
  • Coordinated network of pediatric subspecialists
  • Social work support
  • Neuro-oncology and neurosurgery nurse practitioners
  • Customized radiation oncology treatments
  • Supportive and palliative care specialists
  • Personalized targeted therapy
  • Vaccine and Cellular therapy strategies
  • Wellness and Survivorship Program for long-term follow-up

 

Research and Education Highlights: 

  • Medical student, resident, and fellow rotations
  • Novel drug development targeting mitochondria
  • Medulloblastoma preclinical research
  • Adoptive Cellular Immunotherapy
  • Gene Therapy
  • Stem Cell Transplantation

Return to the top


Primary Immunodeficiencies

The Childhood Primary Immunodeficiency Program at the Maria Fareri Children’s Hospital at Westchester Medical Center and New York Medical College is a multidisciplinary and comprehensive program dedicated to the diagnosis, prevention, treatment and long-term follow up of children diagnosed with primary immunodeficiency syndromes. The program consists of several “state of the art” programs in Newborn Screening, Prevention, Genetic Diagnosis, Stem Cell Transplantation, Reduced Intensity Conditioning and Adoptive Cellular Immunotherapy. The program also provides a unique opportunity for clinical, translational and basic research for students, residents, and fellows focused on the biology and treatment of primary immunodeficiency in children. Most importantly, the program is designed to provide customized and personal care and long-term follow-up to each child with a primary immunodeficiency.

The Primary Immunodeficiency Program is focused on all known immunodeficiencies [Our Clinical Trials, Patient Information], including:

  • Ataxia-Telangiectasia
  • Autoimmune Neutropenia
  • Complement Deficiencies
  • Humoral Immunity
    • Agammaglobulinemia (Bruton’s)
    • Common Variable Immunodeficiency
    • Hyper IgE Syndrome
    • Hyper IgM Syndrome
    • IgA Deficiencies
    • IgM Deficiency
    • Severe Combined Immune Deficiency (SCID)
  • Neutropenia
    • Congenital Neutropenia
    • Cyclic Neutropenia
    • Neonatal Neutropenia
    • Reticular Dysgenesis
    • Wiskott-Aldrich Syndrome
  • Phagocyte Function
    • Chediak-Higashi Syndrome (CHS)
    • Chronic Granulomatous Disease (CGD)
    • Leukocyte Adhesion Deficiency
    • Specific Granule Deficiency

 

Research and Education Highlights:

  • ACGME Accredited Pediatric Hematology, Oncology, and Stem Cell Transplantation Fellowship
  • Member of the Primary Immune Deficiency Treatment Consortium (PIDTC)
  • Student and Resident elective/selectives
  • NYS Newborn screening
  • Comprehensive Genetic Diagnostics
  • Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation
  • Targeted Cellular Therapeutics

 

Unique Features:

  • Comprehensive Genetic Diagnostic Program
  • Genetic Consulting
  • Targeted Immunotherapy
  • Novel Therapeutics
  • Blood and Marrow Transplantation
  • Unrelated Cord Blood Stem Cell Transplantation
  • Unrelated Adult Donor Stem Cell Transplantation
  • Haploidentical Stem Cell Transplantation
  • T-cell Depletion and Stem Cell Selection Transplantation
  • Reduced Intensity Conditioning Therapy
  • Hepa filtered and Positive Pressure Protected Isolation Room
  • Cellular and Tissue Engineering Laboratory
  • Multidisciplinary Team
  • Donor Lymphocyte Infusions

Return to the top


Solid Tumors

The solid tumor program consists of a multidisciplinary team focused on the prevention, diagnosis and treatment of cancers arising in solid organs outside of the cerebrospinal system. The program is also focused on the education of students, residents and fellows who will be conducting scholarly and peer reviewed clinical, translational and basic research in solid tumors.   Furthermore, the Solid Tumor Program has several “state of the art” basic science, translational and clinical research programs in neuroblastoma, kidney, liver, bone, soft tissue and germ cell tumors. Overall, the program is equipped to design and deliver customized and personalized therapy for each child and adolescent diagnosed with a solid tumor.

The program is focused in all aspects of solid tumors occurring in children, adolescents and young adults including neuroblastoma, kidney tumors such as Wilms’ tumor, liver tumors such as hepatoblastoma and hepatocellular carcinoma, bone tumors such as Ewing’s sarcoma and osteosarcoma, soft tissue tumors such as rhabdomyosarcoma, germ cell tumors such as ovarian and testicular tumors.

The Pediatric Solid Tumor Service collaborates with the Division of Gynecologic Oncology and Robotic Gynecologic Surgery for those who may present with gynecologic cancers. The Gynecologic Oncology Division is the Comprehensive Academic Oncologic Gynecology Service for the Hudson Valley Region of New York State, and serves as a major referral center for regions between Albany and the New York City line.  In addition to four Gynecologic Oncologists, specialty services within the Division include Gynecologic Pathology, Radiology, Radiation Therapy, an Infusion Unit, and advanced surgical services including robotics and other minimally invasive and fertility sparing surgery.  Patient treatment decisions are made through the Tumor Board that includes multiple members of the Division’s Gynecologic Oncology team in collaboration with other specialist such as radiation oncologists, medical oncologist and pediatric oncologists.

Solid tumors in children can arise from nearly any organ.  While the mainstay of treatment remains chemotherapy, curing children of these tumors may necessitate complex therapy involving different specialties.  

  • Liver tumors [Our Clinical Trials, Patient Information]:In select cases in addition to chemotherapy, to cure a patient with hepatoblastoma or hepatocellular carcinoma a liver transplant may be necessary.  We work closely with the pediatric liver transplant program at MFCH to identify the best surgical approach for each child. Each case is discussed by a tumor board comprising of pediatric oncologists, hepatologist, pediatric surgeon, liver transplant surgeon, radiologists, radiotherapist and pathologist to determine the best tailored therapy.
  • Kidney tumors [Our Clinical Trials, Patient Information]: The successful treatment of children with Wilms’ tumor or renal cell carcinoma requires more than simply removing the tumor – kidney function must be maintained.  The urologists at MFCH have extensive experience with nephron sparing surgery, which preserves the most normal kidney tissue possible. The appropriate therapy is discussed by a tumor board comprising pediatric oncologists, urologists, radiologists, radiotherapist and pathologist to determine the best therapy for each patient.
  • Sarcomas [Our Clinical Trials, Patient Information]: Musculoskeletal tumors, including osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma can have profound effects on children’s quality of life, as these tumors frequently involve the arms and legs.  Together with our orthopaedic surgeons and radiation oncologists, we can use innovative treatment strategies including limb sparing surgery and radiation therapy (including brachytherapy) to preserve limb function while curing children from their cancers.
  • Germ cell tumors [Our Clinical Trials, Patient Information]: Tumors arising from the ovaries and testes require a nuanced approach to treatment.  Some tumors are cured by a combination of surgery and chemotherapy, while for others, surgery alone will suffice.  The appropriate therapy is discussed by a tumor board comprising pediatric oncologists, urologists, adolescent gynecologists, radiologists and pathologists to determine the best therapy for each patient.
  • Neuroblastoma [Our Clinical Trials, Patient Information]: Neuroblastoma can develop in a variety of places in the body, including the neck, chest, spine, and adrenal glands.  Multimodal therapy including chemotherapy, surgery, radiation therapy, immunotherapy and stem cell transplantation may be used, especially in the setting of advanced disease.  We have state of the art stem cell transplantation capabilities including a cellular and tissue engineering laboratory and our physicians have been pioneers in the field.

Unique Features:

  • Cutting edge customized patient treatment protocols
  • Ten protective isolation hospital rooms for induction therapy and stem cell transplantation
  • Outpatient Infusion Center for patient specific therapies
  • State of the Art Diagnostic Laboratories
  • Local and total body radiation facilities
  • Liver and kidney transplant programs
  • Limb-salvage surgery program
  • Chemo-embolization of liver tumors
  • Kidney (nephron) sparing surgery program
  • Reproduction preservation programs
  • Monoclonal antibody and radio-conjugate antibody therapies
  • Comprehensive Stem and Cellular Therapy and Transplantation Program
  • Cellular and Tissue Engineering Laboratory

Return to the top


Thrombosis & Hemostasis

Our team is dedicated to treat children with bleeding and clotting problems. Team includes physicians, nurses and social workers, with special interest in hemophilia and coagulation factor deficiencies. We also dedicate our care to children with clotting disorders. Beyond the care of children afflicted with these conditions, we also consider family education, social interactions among families of affected children, home care and support as the goal of our team to help parents and families with their inevitable emotional challenges.

We engage in ongoing research for developing innovative therapies and for addressing safety issues, e.g. complications or risks that may be associated with medications. We educate and mentor future trainees in diagnosis and treatment of children and adolescents with bleeding and clotting disorders, and treatment.

Our team is dedicated to care for children with bleeding problems such as:

  • Congenital or acquired bleeding disorders [Our Clinical TrialsPatient Information ]:
    • Hemophilia A (Classical Hemophilia-factor VIII deficiency)
    • Hemophilia B (Christmas disease, factor IX deficiency)
    • Hemophilia C (Factor XI deficiency)
    • Von Willebrand’s disease
  • Rare clotting factor deficiencies [Our Clinical TrialsPatient Information ]:
    • Factor I (fibrinogen deficiency, known as afibrinogenemia or dysfibrinogenemia/hypofibrinogenemia)
    • Factor II (prothrombin)
    • Factor V (parahemophilia)
    • Factor VII
    • Factor X (Stuart factor)
    • Factor XII (Hageman factor)
    • Factor XIII
  • Disorders of the platelets [Our Clinical TrialsPatient Information]:
    • Hermansky-Pudlak syndrome
    • Wiskott Aldrich syndrome
    • Gray platelet syndrome
    • Alpha granule deficiency
    • Bernard Soulier Syndrome or disorders involving fibrinolytic system (e.g. PAI-I deficiency or alpha-2 antiplasmin deficiency)
  • Inherited Disorders of Thrombosis [Our Clinical TrialsPatient Information]:
    • Protein C
    • Protein S
    • Anti-thrombin-III
    • Factor V Leiden
    • Prothrombin gene mutation
    • Anti-phospholipid antibodies
    • Lipoprotein-A
    • Homocysteinemia
    • Elevated fibrinogen
    • Factors VIII, IX, XI
    • Low factor XII

 

Unique Features:

  • All coagulation studies, platelet function tests, and thrombophilia tests are done at the “Special Hematology Laboratory” at Westchester Medical Center
  • Comprehensive Genetics Diagnostics
  • Comprehensive Hemophilia Network
  • Personalized and Customized Care

 

Research and Education Highlights:

  • We participate in clinical trials of new factor products which enables us to try new innovative therapies in children with hemophilia.
  • Student, resident and other allied health professional elective training

Return to the top


As Chief of Pediatric Hematology, Oncology and Stem Cell Transplantation at Maria Fareri Children’s Hospital, Dr. Mitchell Cairo leads a team of researchers to develop and investigate novel strategies of targeted therapies and cellular strategies, including gene therapy and stem cell regenerative therapy, to activate the body’s defense system and to replace damaged cells with thriving ones. Cellular therapy for childhood cancer and blood disorders has become one of the most promising areas of medical research. The promise of unlocking treatments and cures to rare disorders by harnessing the power of the patient’s own body renews the efforts of Dr. Cairo’s team to lead advances that save lives while minimizing unwanted side effects. 

Pediatric Cancer Research Foundation Laboratory

By aligning vast clinical experience with unmatched scientific expertise, the Pediatric Cancer Research Foundation Laboratory centers on six areas of groundbreaking research: 

  • Cancer genetics and treatment of childhood and adolescent hematological malignancies
  • Genetic re-engineering of immune cells to enhance cellular cancer immunotherapy
  • Tumor immunology and target identification for humoral (body-fluid) immunotherapy
  • Stem cell biology, cancer stem cells and regenerative therapy
  • Targeted therapy for childhood, adolescent and young adult tumors
  • Translational (bench to bedside) therapeutic consortiums for childhood and adolescent cancer therapy

In addition, our laboratory has developed several national translational research consortia focusing on stem cell transplantation for high-risk patients with acute leukemia, lymphoma cell therapy, pediatric sarcoma cell therapy, familial stem cell transplantation for sickle cell disease, and non-Hodgkin lymphoma translational research and treatment. Due to our “bench to bedside and back” research, children travel from across the country, and the world, to receive treatment at Maria Fareri Children’s Hospital. 


Cellular and Tissue Engineering Laboratory

The Cellular and Tissue Engineering Laboratory (CTEL) within the Children and Adolescent Cancer and Blood Disease Center at Maria Fareri Children’s Hospital supports a range of translational programs in oncology, hematology, neurology, genetics and cardiology that harness stem sell, cellular, tissue and gene therapies. The laboratory consists of an 8,000 square foot “current good manufacturing practice” (CGMP) facility. But this manufacturing “plant” doesn’t turn out cars, pens, candies, clips or anything that can be seen with the naked eye. Instead, it genetically re-engineers human cells, which is the defining feature of medicine's new frontier. 

The state-of the-art equipment in the CTEL is designed to facilitate cellular therapy (CT) under investigational new drug applications (IND), in support of cellular therapy that will treat a variety of disorders and diseases. All pediatric and adult blood and marrow transplantation programs, and other regenerative cellular therapy programs at Westchester Medical Center and Maria Fareri Children’s Hospital, rely on cell manufacture and processing in the CTEL. 

The research team has Food and Drug Administration approval for several clinical protocols to treat such disorders as sickle cell disease, in which red blood cells break down into a “sickle” shape. Therapeutic action in this case uses the patient’s mother or father as a donor, with peripheral blood as a stem cell source, to replace the damaged sickle cells with healthy red blood cells. Our research team is also investigating a clinical protocol to alleviate the effects of severe hypoxic ischemic encephalopathy, the lack of oxygen delivered to a baby's brain, resulting in neuron injury, cell death, and compromised brain, heart and motor function. In this protocol, stem cells from the newborn's cord blood work with stem cells derived from the newborn's placenta to support cell recovery. 

Bringing these therapies to fruition allows Maria Fareri Children's Hospital, and the Westchester Medical Center Health Network, to create and provide patient-specific therapies without requiring patients to travel far from home. Our aim to bring tomorrow's therapies to patients today invigorates our mission to advance medicine, provide state-of-the-art care, and keep all children happy and healthy.

Pediatric Hematology/Oncology
Maria Fareri Children’s Hospital
100 Woods Road
Valhalla, NY 10595
914.493.7997


By Car

Train

Maria Fareri Children’s Hospital is served by Metro North's Harlem line via two stations:

• White Plains - Bus transfer options available
• Hawthorne - Taxi service available

For train fare and schedule information, call 1-800-METRO-INFO or go to www.mta.info/mnr.


Bus

There are three bus lines (Westchester Bee Line) you can take to our campus. Please call 914.813.7777 for bus routes and fares.


Campus Map

The Westchester Medical Center campus includes the Maria Fareri Children's Hospital and the Behavioral Health Center.

Maria Fareri Children’s Hospital, a member of the Westchester Medical Center Health Network, and the Westchester Warriors Youth Hockey Program unveiled Westchester Warriors Way – a new entrance to the expanded Center for Pediatric Oncology and Cellular Therapy at Maria Fareri Children’s Hospital.

Since 2016, the Westchester Warriors Youth Hockey Program has partnered with Maria Fareri Children’s Hospital to fight children’s cancer, a mission started by Westchester Warriors Co-Founders Luis Panchame, Denis DuFresne and Ron Vitale. To date, the Westchester Warriors have raised over $230,000 for Maria Fareri Children’s Hospital, and the club’s efforts will continue throughout the year.

Scroll Down for Photos

Pictured, from left, Michael Gewitz, MD, William Russell McCurdy Physician-in-Chief at Maria Fareri Children’s Hospital (back row left), Michael Israel, President and CEO, Westchester Medical Center Health Network (second left) and Mitchell Cairo, MD, Chief of Pediatric Hematology, Oncology & Stem Cell Transplantation at Maria Fareri Children’s Hospital (second row center) join Westchester Warriors Youth Hockey Club Co-Founders Luis Panchame (back row center), Ron Vitale (second right) and Denis Dufresne (far right) help Westchester Warriors Youth Hockey Club players and fans celebrate the opening of Westchester Warriors Way at Maria Fareri Children’s Hospital.

Westchester Warriors Youth Hockey Club Co-Founders Luis Panchame (left), Denis Dufresne and Ron Vitale in front of the plaque commemorating Westchester Warriors Way at Maria Fareri Children’s Hospital.

Mitchell Cairo, MD, Chief of Pediatric Hematology, Oncology & Stem Cell Transplantation at Maria Fareri Children’s Hospital reveals the plaque commemorating the opening of Westchester Warriors Way at Maria Fareri Children’s Hospital. Looking on are Michael Israel, President and CEO, Westchester Medical Center Health Network (left) and Westchester Warriors Youth Hockey Club Co-Founder Luis Panchame.

Commemorative plaque adorns the wall outside of Westchester Warriors Way, a new entry point for children and families entering Center for Pediatric Oncology and Cellular Therapy at Maria Fareri Children’s Hospital.

Westchester Warriors Youth Hockey Club jersey’s share the club’s mission and message.

Dozens of players, families and hospital representatives attended the dedication ceremony for Westchester Warriors Way.

Cairo, Mitchell
Cairo, Mitchell
‌Chief, Pediatric Hematology, Oncology and Stem Cell Transplantation‌; Director, Childhood and Adolescent Cancer and Blood Diseases Center
Pediatric Hematology-Oncology
Pediatrics
Braniecki, Suzanne
Pediatric Hematology-Oncology
Pediatric Neuropsychology
Pediatrics
Flower, Allyson
Pediatric Hematology-Oncology
Pediatrics
Hochberg, Jessica
Pediatric Hematology-Oncology
Pediatrics
Ozkaynak, Mehmet
Pediatric Hematology-Oncology
Pediatrics
Rosenblum, Jeremy
Pediatric Hematology-Oncology
Pediatrics
Sandoval, Claudio
Pediatric Hematology-Oncology
Pediatrics
Tugal, Oya
Pediatric Hematology-Oncology